A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
- Registration Number
- NCT04547166
- Lead Sponsor
- Shanghai Henlius Biotech
- Brief Summary
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)
- Detailed Description
Patients with confirmed unresectable metastatic/recurrent colorectal adenocarcinoma who have not received systemic anti-neoplastic therapy for metastatic/recurrent lesions will be included in this study.Approximately 6-12 patients will be enrolled in the Part I (Safety Run-in Period).Approximately 100 patients will be enrolled in the Part II (Phase II study, 50 in the test group and 50 in the control group).Approximately 568 patients will be enrolled in the Part III (Phase III study, 284 in the test group and 284 in the control group).
Part II (Phase II study): Approximately 40 study sites in China will participate.
Part III (Phase III study): A total of approximately 75 study sites in 3 countries(including China, Japan, Indonesia) will participate.
The study consists of a screening period (up to 28 days), a treatment period (3-week cycle, up to 2 years), and a follow-up period (including a safety follow-up period, and a survival follow-up every 12 weeks).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 568
- Histopathologically confirmed unresectable metastatic/recurrent colorectal adenocarcinoma
- Life expectancy ≥ 12 weeks
- Have not received any previous systemic anti-tumor drug treatment for metastatic colorectal adenocarcinoma
- For participants who have previously received neoadjuvant/adjuvant therapy, the time from the last treatment to recurrence or progression must exceed 12 months.
- With at least one measurable lesion as assessed by the IRRC per RECIST v1.1, and the measurable lesion should not have been treated locally such as with radiotherapy (a lesion located in an area subjected to previous radiotherapy can also be regarded as a measurable lesion if PD is confirmed)
- Agree to provide sufficient previously preserved tumor tissue specimens or agree to undergo biopsy to collect tumor tissue for some gene test.
- Have an ECOG PS score of 0 or 1 within 7 days prior to receiving the first dose of the study drugs
- Have Adequate major organ functions.
Key
-
Have confirmed MSI-H CRC (gene test)
-
Subjects with oligometastatic liver disease and presenting the potential for becoming resectable
-
Presence of central nervous system (CNS) or leptomeningeal metastases
-
Have received radiotherapy within 6 months prior to the initiation of study treatment, except for palliative radiotherapy for bone disorders at least 14 days prior to initiation of study treatment; radiotherapy covering more than 30% of the bone marrow area within 28 days prior to randomization is not allowed.
-
With a history of or current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, severe pulmonary dysfunction, or any condition that may interfere with the detection and management of suspected drug-related pulmonary toxicity
-
Have received major surgery within 28 days prior to randomization. A major surgery in this study is defined as a surgery requiring at least 3 weeks of recovery to be able to receive the treatment in this study
-
Previously received intestinal stent implantation, with the stent remaining in place at the screening period
-
Uncontrolled hypertension despite clinical treatment (defined as systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg)
-
With a history of hypertensive crisis or hypertensive encephalopathy
-
With a history of significant/severe hemorrhage within 1 month prior to randomization, or have received blood transfusion within 2 weeks prior to randomization
-
Requiring long-term treatment with daily administration of nonsteroidal anti-inflammatory drugs (NSAIDs). Occasional use of NSAIDs to relieve medical symptoms such as headache or pyrexia is allowed
-
With evidence showing the presence of meteorism that cannot be attributed to puncture or recent surgery
-
Presence of severe, unhealed or split wounds and active ulcers or untreated fractures
-
Presence of any of the following medical conditions within 6 months prior to randomization:
- Abdominal or tracheoesophageal fistula, gastrointestinal perforation or intra-abdominal abscess, massive ascites as judged by the investigator (defined as patients requiring drainage or treatment within two weeks)
- Intestinal obstruction and/or previous clinical signs or symptoms of gastrointestinal obstruction, including incomplete obstruction associated with a preexisting disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding. 2 months prior to randomization, patients with previous symptoms of incomplete obstruction/obstructive syndrome/signs/symptoms of intestinal obstruction that have improved after treatment may be enrolled in the study as assessed by the investigator
- Severe, uncontrollable intra-abdominal inflammation requiring clinical intervention as judged by the investigator
- Major vascular disease (e.g., aortic aneurysm requiring surgical repair or associated with recent peripheral artery thrombosis)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Serplulima +Bevacizumab+XELOX HLX10 Serplulimab (HLX10) in Combination With Bevacizumab and chemotherapy (XELOX) Serplulima +Bevacizumab+XELOX HLX04、 Serplulimab (HLX10) in Combination With Bevacizumab and chemotherapy (XELOX) placebo + Bevacizumab+XELOX HLX04、 placebo in combination with Bevacizumab and chemotherapy (XELOX)
- Primary Outcome Measures
Name Time Method PFS From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months Progression-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)
- Secondary Outcome Measures
Name Time Method OS From date of randomization until the date of first date of death from any cause, assessed up to 100 months Overall survival (OS)
PFS From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months Progression-free survival (assessed by the investigators based on RECIST v1.1)
ORR through study completion, an average of 1 year Objective response rate (assessed by independent radiological review and the investigators based on RECIST v1.1))
Duration of response from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years Duration of response
DCR the proportion of patients with the best overall response of CR, PR, or stable disease (SD) persisting for 12 weeks Disease control rate
PFS2 From date of randomization until the date of the second documented PD as assessed by the investigator or date of death from any cause, whichever came first, assessed up to 100 months Progression-free survival in the next line of treatment(assessed by the investigators based on RECIST v1.1)
Trial Locations
- Locations (5)
Center for Cancer Prevention and Treatment of Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Linyi Cancer Hospital
🇨🇳Linyi, China
Fudan University Affiliated Oncology Hospital
🇨🇳Shanghai, China
National Cancer Center
🇯🇵Kashiwa, Japan
Center for Cancer Prevention and Treatment of Sun Yat-sen University🇨🇳Guangzhou, Guangdong, ChinaRuihua XuContact020-87343292xurh@sysucc.org.cn